Incyte Pharmaceuticals, Inc.

Incyte Corporation

Benjamin Graeme Cocks

Janice K Au-Young

Jeffrey J Seilhamer

Roger T Coleman

Jennifer L Hillman

Surya K Goli

Douglas A Fisher

Susan G Stuart

Timothy J Maslyn

Rachel J Cheng

James R Kerr

Steven M Lassagne

Srikar D Rao

Timothy M Engler

The present invention provides polynucleotide and amino acid sequences which encode and identify a novel human myeloid terminal differentiation response gene designated MYD118. The present invention also provides for myd118 antisense molecules. The invention further provides genetically engineered expression vectors and host cells for the production of purified MYD118 polypeptide; antibodies, antagonists and inhibitors of MYD118 polypeptide; and pharmaceutical compositions and methods of treatment based on polynucleotide sequences encoding MYD118 and MYD118 polypeptide. The invention specifically provides for use of the myd118 polynucleotide sequences as a diagnostic composition for the detection of myeloproliferative diseases and leukemias. The invention also relates to therapeutic methods and compositions based upon the nucleotide sequences for myd118. The invention further provides antibodies which specifically bind to MYD118.

Human myeloid terminal differentiation response gene

The present invention relates to a composition comprising a plurality of polynucleotide probes. The composition can be used as hybridizable array elements in a microarray. The present invention also relates to a method for selecting polynucleotide probes for the composition.

Compositions for the detection of blood cell and immunological response gene expression

A biomolecular expression information processing system has procedures and tables that store abundance datasets and hybridization data. The tables also store information identifying a microarray technology type for each hybridization and microarray design information for each microarray technology type. The microarray design information includes technology data that specifies global characteristics of each microarray, and array element data that specifies characteristics of array elements in each microarray instance of the microarray technology type. The procedures process the abundance datasets in accordance with the microarray design information associated with each such abundance dataset. The system stores technology data for multiple distinct microarray technology types and stores array element data for multiple microarray designs of a single technology type.

System and method for generating, analyzing and storing normalized expression datasets from raw expression datasets derived from microarray includes nucleic acid probe sequences

The invention provides human cyclic nucleotide phosphodiesterases (PDE8) and polynucleotides which identify and encode PDE8. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating or preventing disorders associated with expression of PDE8.

Cyclic nucleotide phosphodiesterases

The present invention provides a polynucleotide (mctl) which identifies and encodes a novel human C-type lectin (MCTL). The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequence encoding MCTL. The invention also provides for the use of substantially purified MCTL and its agonists in the commercial production of recombinant proteins and in pharmaceutical compositions for the treatment of diseases associated with the expression of MCTL. Additionally, the invention provides for the use of antisense molecules to mctl in pharmaceutical compositions for treatment of diseases associated with the expression of MCTL. The invention also describes diagnostic assays which utilize diagnostic compositions comprising the polynucleotide, fragments or the complement thereof, which hybridize with the genomic sequence or the transcript of mctl. The present invention also relates to anti-MCTL antibodies which specifically bind to MCTL.

Human C-type lectin

The present invention relates to a heretofore uncharacterized family of cyclic nucleotide phosphodiesterases (CN PCD8) and provides specific polynucleotide and amino acid sequences which encode and identify CN PDE8 family members designated herein as CN PDE8A and CN PDE8B. The present invention also relates to the use of proteins, peptides and organic molecules capable of modulating CN PDE8 activity to inhibit or enhance phosphodiesterase activity associated with disease. The present invention further relates to the use of CN PDE8 and genetically engineered host cells that express CN PDE8 to evaluate and screen for substances and compounds that modulate cyclic nucleotide phosphodiesterase activity. The present invention also provides for cn pde8 antisense molecules. The invention provides genetically engineered expression vectors and host cells for the production of purified CN PDE8 polypeptide. The present invention further provides pharmaceutical compositions and methods of treatment based on the identification of agonist, antagonists and inhibitors of CN PDE8. The invention specifically provides for use of the cn pde8 polynucleotide sequences as a diagnostic composition for the detection of disease.

Growing community of inventors

Palo Alto, CA, United States of America

Benjamin Graeme Cocks